icagen advancing early drug discovery
Richie Cunningham is currently CEO of Icagen Inc. He brings over 20 years of leadership experience in the healthcare and biopharmaceutical industry with Premier Inc., Valeant Pharmaceuticals, Boehringer Ingelheim, and XRpro Sciences Inc. (now Icagen Inc.). His various leadership roles include strategy development, contracting and negotiations, marketing and sales, as well as leading integrations and business development activities in the biopharma industry. Mr. Cunningham has also led the commercialization and launch of multiple products in the Infectious Disease, Dermatology, Oncology, Cardiovascular, Respiratory and Diabetes therapeutic areas. Mr. Cunningham joined Icagen Inc. in late November of 2014 and has since led the company through two transformational acquisitions from Pfizer and Sanofi in July 2015 (Pfizer, North Carolina Site) and July 2016 (Sanofi, Arizona Site). He has led the company from a single technology in XRpro to a research team with leading expertise in the early drug discovery phase through these key strategic acquisitions. In addition to establishing his healthcare career, Richie also excelled as a professional athlete in the NFL holding All-Pro honors for the Dallas Cowboys, Green Bay Packers, then later the Carolina Panthers and Jacksonville Jaguars. His career in the NFL spanned from 1994 until his retirement in 2002.